Ensysce Biosciences, Inc.
ENSC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $1 | $1 |
| % Growth | -64% | 3.9% | 1.3% | – |
| Cost of Goods Sold | $3 | $2 | $0 | $4 |
| Gross Profit | -$2 | -$1 | $1 | -$2 |
| % Margin | -499.2% | -40.2% | 100% | -191.7% |
| R&D Expenses | $3 | $2 | $2 | $4 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3 | -$2 | -$0 | -$4 |
| Operating Expenses | $1 | $1 | $3 | $1 |
| Operating Income | -$4 | -$2 | -$2 | -$4 |
| % Margin | -758.7% | -127.6% | -149.1% | -274.3% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$4 | -$2 | -$2 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$2 | -$2 | -$4 |
| % Margin | -756.3% | -126.4% | -147.4% | -273.4% |
| EPS | -1.29 | -0.79 | -1.39 | -2.9 |
| % Growth | -63.3% | 43.2% | 52.1% | – |
| EPS Diluted | -1.29 | -0.79 | -1.39 | -2.9 |
| Weighted Avg Shares Out | 3 | 2 | 1 | 1 |
| Weighted Avg Shares Out Dil | 3 | 2 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $2 | $0 | $4 |
| EBITDA | $0 | $0 | -$2 | $0 |
| % Margin | 3.7% | 0% | -147.1% | 0% |